Protein Tyrosine Phosphatase-1B Inhibitory Activity of Isoprenylated Flavonoids Isolated from Erythrina mildbraedii
Inhibition of protein tyrosine phosphatase-1B (PTP1B) has been proposed as a therapy for treatment of type-2 diabetes and obesity. Bioassay-guided fractionation of an EtOAc-soluble extract of the root bark of Erythrina mildbraedii, using an in vitro PTP1B inhibitory assay, resulted in the isolation...
Saved in:
Published in: | Journal of natural products (Washington, D.C.) Vol. 69; no. 11; pp. 1572 - 1576 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Washington, DC
American Chemical Society
01-11-2006
Glendale, AZ American Society of Pharmacognosy |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Inhibition of protein tyrosine phosphatase-1B (PTP1B) has been proposed as a therapy for treatment of type-2 diabetes and obesity. Bioassay-guided fractionation of an EtOAc-soluble extract of the root bark of Erythrina mildbraedii, using an in vitro PTP1B inhibitory assay, resulted in the isolation of three new isoprenylated flavonoids, abyssinone-IV-4‘-O-methyl ether (2), 7-hydroxy-4‘-methoxy-3‘-(3-hydroxy-3-methyl-trans-but-1-enyl)-5‘-(3-methylbut-2-enyl)flavanone (3), and abyssinone-VI-4-O-methyl ether (6), along with six known flavonoids, abyssinone-V-4‘-O-methyl ether (1), abyssinone-V (4), abyssinone-IV (5), sigmoidin E (7), 4‘-hydroxy-5,7-dimethoxyisoflavone (8), and alpinumisoflavone (9). Compounds 1 and 2, 4−7, and 9 inhibited PTP1B activity, with IC50 values ranging from 14.8 ± 1.1 to 39.7 ± 2.5 μM. On the basis of the data obtained, flavanones and chalcones with isoprenyl groups may be considered as a new class of PTP1B inhibitors. |
---|---|
Bibliography: | http://dx.doi.org/10.1021/np0601861 Part 48 in the series “Erythrina Studies”. ark:/67375/TPS-KT3DKZX0-8 istex:51E8E68654E8F33C0367B2531F873433885EC4EF ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0163-3864 1520-6025 |
DOI: | 10.1021/np0601861 |